Spinosad 0.9% in the Treatment of Scabies: Efficacy Results from Two Multicenter, Randomized, Double-Blind, Vehicle-Controlled Studies1
Given the known limitations with neurotoxic scabicides2, a recent article in the Journal of the American Academy of Dermatology highlights Spinosad 0.9% as the only prescription treatment that meets new FDA criteria for a “complete cure” of scabies based on two phase III, multi-center, randomized, double-blind, vehicle-controlled clinical trials.
A summary of the efficacy data follows:1
- As targeted topical therapy, Spinosad 0.9% represents a new scabies treatment option for physicians and patients who otherwise have few choices.
- Spinosad 0.9% has the potential to be an effective treatment for scabies due to its ability to reach mites in the stratum corneum (ie., where they feed and reproduce).
- Based on AE reporting, Spinosad 0.9% appeared well-tolerated by subjects as young as 4 years of age and did not raise safety concerns.
Visit www.natroba.com/scabies/
to learn more about the only targeted topical therapy that meets the new FDA criteria for a “complete cure”.3
Reference(s)
- Seiler JC, et al. J Am Acad Dermatol. 2021;doi:10.1016/j.jaad.2021.07.074.
- Gopinath H et al. Int J Dermatol. 2018;57(11):1293-1298.
- ParaPRO, LLC & Concentrics Research (2018). A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy and Pharmacokinetics of Natroba™ for the Treatment of Scabies (Clinical Study Protocol, Amd. 6.0, pp. 1-66).
NAT-SLJA-000